Liposomal Aminoglycoside Manufacturing for Scaled Encapsulation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to scale up the production of liposomal formulations of aminoglycosides like amikacin while maintaining consistent parameters such as drug concentration, lipid-to-drug ratio, encapsulation efficiency, and particle size for clinical and commercial use.
Innovation Solution
A method for large-scale manufacturing of liposomal aminoglycosides involves mixing a lipid stream with an aminoglycoside stream to form a combined lipid-aminoglycoside stream, which is then mixed with an aqueous saline solution in a reaction vessel, using a turbulent flow process to achieve a high aminoglycoside-to-lipid ratio and encapsulation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If liposomal formulations are scaled up from bench scale to commercial manufacturing scale, then production volume increases, but consistency of parameters such as drug concentration, lipid-to-drug ratio, encapsulation efficiency, and particle size deteriorates
Solution Approach 1:
The patent modifies critical process parameters including lipid-to-drug ratio (targeting less than 1:1, preferably 0.5:1 to 0.9:1), encapsulation efficiency (targeting at least 40%), and flow rates of lipid and aminoglycoside streams. These parameter changes enable consistent high-quality liposomal formulations at commercial scale while maintaining high aminoglycoside loading
Solution Approach 2:
The patent implements process monitoring and control mechanisms to track encapsulation efficiency, lipid-to-drug ratio, and particle size distribution during manufacturing. This feedback system allows real-time adjustments to maintain parameter consistency despite scale-up challenges
2Quantity of substance
If high aminoglycoside loading is achieved in liposomes, then drug concentration increases, but manufacturing complexity increases
Solution Approach 1:
The patent prepares lipid and aminoglycoside streams separately with pre-determined concentrations and flow rates before mixing. The lipid stream is prepared at a controlled ratio relative to the aminoglycoside stream, ensuring high drug loading is achieved systematically rather than through complex post-processing
Solution Approach 2:
The manufacturing process is divided into separate streams: a lipid stream and an aminoglycoside stream, which are mixed in controlled proportions. This segmentation simplifies the manufacturing of high-loading formulations by decoupling the preparation of lipid and drug components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method ensures a high encapsulation efficiency of at least 40% and a lipid-to-aminoglycoside weight ratio of less than 1:1, producing liposomes with consistent particle sizes suitable for clinical use.
Implementation Method 1
using a turbulent flow process to achieve a high aminoglycoside-to-lipid ratio and encapsulation efficiency
Data Source
AI summary
Provided herein are large-scale manufacturing methods for drug formulations containing an aminoglycoside such as amikacin. The method utilizes mixing a first stream comprising DPPC and cholesterol with a second stream comprising amikacin sulfate at particular flow rates to obtain a drug formulation with a superior encapsulation efficiency. The processes described herein address the need for preparing aminoglycoside drug formulations at commercial scale.